10/17/2006 | BT | Market Commentary: Icos gains 16% on Lilly buyout; Millennium forfeits AnorMED; InterMune rises 25%; OSI better
|
10/6/2006 | BT | Market Commentary: Acorda up 10% as Elan, Biogen ease on Tysabri news; Panacos up on takeover; Memory up on PIPE
|
10/3/2006 | BT | Market Commentary: Acorda shoots up 32%; Isis lower after analyst day; Gilead off 3.5%, Myogen eases; Amgen better
|
10/2/2006 | BT | Gilead agrees to acquire Myogen through $2.5 billion transaction
|
10/2/2006 | BT | Market Commentary: Gilead off, Myogen skyrockets; Accentia up, Biovest off; GTC up after close; Encysive off 3%
|
9/7/2006 | BT | Myogen starts phase 3 trial of ambrisentan in pulmonary hypertension
|
8/7/2006 | BT | Market Commentary: Encysive sinks on dilution worries; Acorda higher; Genitope gains; Ariad off
|
7/25/2006 | BT | Market Commentary: Encysive plunges 40%; Momenta gains 38%; Nastech rises; Enzon up; Connetics firms
|
7/21/2006 | BT | Market Commentary: Amgen stronger; ReGen cheered; Cleveland BioLabs debuts lower; Amylin, Nektar weaker
|
7/11/2006 | BT | Myogen extends drug discovery collaboration with Novartis
|
6/5/2006 | BT | Myogen starts phase 3 trial of darusentan for resistant hypertension
|
5/18/2006 | BT | Market Commentary: Neurocrine piles on more losses; DOV adds back 10%; Celgene sees buying on dip; Exelixis up
|
5/16/2006 | BT | Myogen presents additional results from phase 2b clinical trial of darusentan
|
5/8/2006 | BT | Myogen 1Q revenues increase to $3.8 million, ambrisentan closer to commercialization
|
5/8/2006 | BT | Market Commentary: Monogram Biosciences stock jumps on $25 million Pfizer financing; Myogen releases 1Q earnings
|
5/3/2006 | BT | Myogen says ambrisentan trials meet efficacy endpoint
|
4/10/2006 | BT | Myogen says ambrisentan meets endpoints in trial, gets $5.25 million milestone payment
|
3/24/2006 | BT | Market Commentary: BioMarin shares, new bonds gain; Cephalon loses 13%; Idenix falls 28%; King slips; Encysive declines
|
2/13/2006 | BT | Myogen's study of ambrisentan for pulmonary arterial hypertension shows positive top line results
|
2/2/2006 | BT | Myogen sells European subsidiary to Wülfing for $6.1 million plus royalty
|
12/12/2005 | BT | Myogen: ambrisentan effective in phase 3 study of hypertension
|
12/12/2005 | BT | Market Commentary: MedImmune up on flu drug data; Merck stock off on Vioxx mistrial; Encysive falls on Myogen's gain
|
11/16/2005 | BTCV | Myogen files $250 million shelf
|
11/10/2005 | BT | Myogen achieves enrollment for phase-3b trial of ambrisentan to treat hypertension
|
9/21/2005 | BT | Myogen greenshoe exercised, raising stock sale to $125 million
|
9/16/2005 | BT | New Issue: Myogen raises $101 million net in follow-on at $23.25 vs. $23.96 close
|
9/16/2005 | BT | Market Commentary: Meridian Biosciences slips in spot deal; Myogen, Geron deals show improved reception
|
9/15/2005 | BT | Market Commentary: Myogen, Geron follow-ons at bat; ViroPharma up; Advancis almost doubles; GTx launches new deal
|
9/14/2005 | BT | Market Commentary: Progenics off on spot sale; profits taken on Celgene rise; Cubist off; Access dives on bankruptcy fears
|
9/13/2005 | BT | Market Commentary: Immunomedics up; OSI rebounds; Celgene retreats; Protein Design Labs, Novavax, Cephalon all up
|
9/12/2005 | BT | Geron joins Myogen for Thursday; Cell Genesys up on back of Geron; OSI Pharma plummets on Tarceva
|
9/9/2005 | BT | Market Commentary: Genomic talk surfaces; Voyager files IPO; Elan joins Biogen fall on restructuring; Sepracor lifted
|
9/8/2005 | BT | Myogen plans follow-on sale of 4 million shares Sept. 15 via Goldman
|
9/8/2005 | BT | Market Commentary: Myogen, NPS float follow-ons; Nektar halted during FDA panel; Sepracor up in face of generic filing
|
8/18/2005 | BT | Market Commentary: Myogen shoots higher on trial data; Par Pharma buyers hoping for deal; Del Labs bonds fall; Cephalon up
|
8/2/2005 | BT | Market Commentary: Anadys up on Novartis details; Ariad, Nastech, ZymoGenetics mixed; Myogen zooms; Isis gains
|
6/3/2005 | CV | Myogen files $125 million shelf
|